Sanofi Consumer Healthcare India Limited has informed the Exchange regarding Appointment of M/s. Kishore Bhatia & Associates as Cost Auditors of the company w.e.f. January 01, 2026.
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved audited standalone financial results for Q4 and FY ended December 31, 2025. Revenue from operations rose about 21% YoY to Rs. 8,784 million, while net profit grew roughly 33% to Rs. 2,401 million; Q4 revenue jumped to Rs. 2,510 million with profit of Rs. 665 million. The board recommended a final dividend of Rs. 75 per share (on Rs. 10 face value) subject to shareholder approval. Statutory auditors Kalyaniwalla & Mistry LLP issued an unmodified opinion, and M/s. Kishore Bhatia & Associates was re-appointed as Cost Auditor for FY2026.
Strong topline and profit growth with a healthy dividend payout should be viewed positively by shareholders. The change in ultimate parent to Opal JVco (post-Sanofi's 50% Opella stake sale) is a structural shift to keep in mind, though day-to-day operations remain unaffected.